T Cell News and Research

Latest T Cell News and Research

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

Inovio SynCon avian influenza vaccine demonstrates broad coverage

Inovio Pharmaceuticals, Inc. announced today that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.

17 May 2012

Lenalidomide following stem cell transplant can halt progression of blood cancer

Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid-, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.

17 May 2012

Cardiac ischemia plays an important role in adenovector gene transfection in mammalian hearts

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA.

17 May 2012

Breast cancer cell surface protein blows cover of potent tumor-generating cells

Breast cancer stem cells wear a cell surface protein that is part nametag and part bull's eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation.

17 May 2012

CHOP researcher leads trial of ALK inhibitor in neuroblastoma, lymphoma

A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.

17 May 2012

Study reveals pathway that may help slow development of multiple myeloma

Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs.

17 May 2012

Gene therapy restores movement in children bedridden with AADC

Using gene transfer techniques pioneered by University of Florida faculty, Taiwanese doctors have restored some movement in four children bedridden with a rare, life-threatening neurological disease.

17 May 2012

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

First trial to investigate new drug combination for NSCLC

Cancer Research UK's Drug Development Office has opened the first trial of a new drug combination in patients with advanced solid tumours and in a subset of patients who have non-small cell lung cancer. This trial will combine two compounds that aim to starve the tumours while simultaneously blocking cancer cell growth.

17 May 2012

High-throughput sequencing can detect early signs of leukemia relapse

A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.

17 May 2012

Smartphones can improve QOL for people with poor vision

iPhones and other smartphones can be a huge help to the visually impaired, but few vision doctors are recommending them to patients, according to a study co-authored by a Loyola University Chicago Stritch School of Medicine ophthalmologist.

17 May 2012

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Ibrutinib shows promise against CLL in the elderly

The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.

17 May 2012

New method resolves cell structure and dynamics of living fish larvae

Microscopes provide valuable insights in the structure and dynamics of cells, in particular when the latter remain in their natural environment. However, this is very difficult especially for higher organisms. Researchers of Karlsruhe Institute of Technology (KIT), the Max Planck Institute for Polymer Research, Mainz, and the American National Institutes of Health (NIH) have now developed a new method to visualize cell structures of an eighth of a micrometer in size in living fish larvae.

17 May 2012

Project aims to find new diagnostic tools, drugs for triple negative breast cancer

Some types of breast cancer can be successfully treated with drugs such as tamoxifen, but treatment for a type of breast cancer more common in young and black women is still limited to radiation and general chemotherapy. Called triple negative breast cancer, this type of cancer is the focus of a 20-month, $8.6-million research project that aims to find new diagnostic tools and options for drugs.

17 May 2012

Biologists engineer algae to produce potential candidates for malarial vaccine

Biologists at the University of California, San Diego have succeeded in engineering algae to produce potential candidates for a vaccine that would prevent transmission of the parasite that causes malaria, an achievement that could pave the way for the development of an inexpensive way to protect billions of people from one of the world's most prevalent and debilitating diseases. Initial proof-of-principle experiments suggest that such a vaccine could prevent malaria transmission.

17 May 2012

Combination of daclizumab and vaccine improves survival of breast cancer patients

A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab.

17 May 2012

Dialysis patients can benefit from talking control support therapy

The constant health education that dialysis patients receive can lead to boredom and noncompliance. But a Loyola University Medical Center study has found that brief, casual chats can be a significant benefit to patients.

17 May 2012

May issue of NeuroPerspective assesses field of stroke therapeutics

NeuroPerspective, the independent, monthly review of the neurotherapeutics area, has released its May issue, which assesses the field of therapeutics for stroke.

17 May 2012